Johannesburg. Aspen (APN), South Africa’s leading pharmaceutical company, has announced that Irish-based Tibotec Pharmaceuticals has granted it a non-exclusive license to manufacture, market and distribute the Anti-retroviral (“ARV”) compound, rilpivirine hydrochloride (TMC278), pending approval of the molecule which could then be prescribed for patients commencing ARV treatment for the first time as well as for… Continue reading Aspen granted generic license for the manufacture and supply of TMC278
Aspen is in a closed period from 1st July 2025 until the publication of the annual results on the JSE SENS platform on the 3rd September 2025.
